Detailansicht

Wissensnetz

Person

Maher Hanoun (1980-)

Arzt

Name	Maher Hanoun
Zeit	1980- (Lebensdaten)
Ort	Deutschland
Beruf	Arzt (charakteristischer Beruf)
Beziehung	Universitätsklinikum Essen. Klinik für Hämatologie
Weitere Angaben	Diss. Fachbereich Medizin Seit 2014 Oberarzt an der Klinik für Hämatologie des Universitätsklinikums Essen
Quelle	Homepage: https://www.uni-essen-haematologie.de/aerztliche-mitarbeiter/ LinkedIn: https://www.linkedin.com/in/maher-hanoun-63570b7a/
Datensatztyp	Person
GND-Nummer	135901359
Datensatz-ID	135901359
Beteiligt an alle anzeigen Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles Alterations of cohesin complex genes in acute myeloid leukemia : differential co-mutations, clinical presentation and impact on outcome CD38-Inhibition als neuer Therapieansatz für die akute myeloische Leukämie Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial Rauchen und Sexualhormone als Einflussfaktoren der endokrinen Orbitopathie bei Morbus Basedow Rauchen und Sexualhormone als Einflussfaktoren der endokrinen Orbitopathie bei Morbus Basedow

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Maher Hanoun (1980-)

Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

Alterations of cohesin complex genes in acute myeloid leukemia : differential co-mutations, clinical presentation and impact on outcome

CD38-Inhibition als neuer Therapieansatz für die akute myeloische Leukämie

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial

Rauchen und Sexualhormone als Einflussfaktoren der endokrinen Orbitopathie bei Morbus Basedow

Rauchen und Sexualhormone als Einflussfaktoren der endokrinen Orbitopathie bei Morbus Basedow